Commerzbank Aktiengesellschaft FI Has $9.41 Million Position in Pfizer Inc. (NYSE:PFE)

Commerzbank Aktiengesellschaft FI cut its position in Pfizer Inc. (NYSE:PFE - Free Report) by 5.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 371,370 shares of the biopharmaceutical company's stock after selling 21,983 shares during the period. Commerzbank Aktiengesellschaft FI's holdings in Pfizer were worth $9,411,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Forum Financial Management LP increased its position in shares of Pfizer by 8.1% during the first quarter. Forum Financial Management LP now owns 104,496 shares of the biopharmaceutical company's stock worth $2,648,000 after acquiring an additional 7,851 shares in the last quarter. Easterly Investment Partners LLC increased its position in shares of Pfizer by 262.4% during the first quarter. Easterly Investment Partners LLC now owns 70,668 shares of the biopharmaceutical company's stock worth $1,791,000 after acquiring an additional 51,168 shares in the last quarter. Kingsview Wealth Management LLC increased its position in shares of Pfizer by 14.2% during the first quarter. Kingsview Wealth Management LLC now owns 181,867 shares of the biopharmaceutical company's stock worth $4,609,000 after acquiring an additional 22,586 shares in the last quarter. Members Trust Co increased its position in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after acquiring an additional 467 shares in the last quarter. Finally, Bailard Inc. grew its position in Pfizer by 3.4% in the first quarter. Bailard Inc. now owns 55,214 shares of the biopharmaceutical company's stock valued at $1,399,000 after purchasing an additional 1,840 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.02 during mid-day trading on Thursday, reaching $24.59. 47,333,190 shares of the company were exchanged, compared to its average volume of 41,955,789. The company's 50-day simple moving average is $23.99 and its 200-day simple moving average is $24.77. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $139.83 billion, a P/E ratio of 17.82, a P/E/G ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the company posted $0.82 EPS. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.99%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. TD Cowen decreased their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Bank of America raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Jefferies Financial Group raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. BMO Capital Markets decreased their target price on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.